Alzamend Neuro, Inc.
ALZN
$1.89
-$0.03-1.56%
NASDAQ
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.83% | -14.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 120.19% | -63.04% | |||
| Operating Income | -120.19% | 63.04% | |||
| Income Before Tax | -119.72% | 62.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -119.72% | 62.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -119.72% | 62.97% | |||
| EBIT | -120.19% | 63.04% | |||
| EBITDA | -123.62% | 63.69% | |||
| EPS Basic | -95.27% | 76.93% | |||
| Normalized Basic EPS | -95.24% | 76.94% | |||
| EPS Diluted | -95.27% | 76.93% | |||
| Normalized Diluted EPS | -95.24% | 76.94% | |||
| Average Basic Shares Outstanding | 12.53% | 60.54% | |||
| Average Diluted Shares Outstanding | 12.53% | 60.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||